Meningiomas usually can be readily diagnosed on H&E alone, although occasionally immunohistochemistry (IHC) confirmation is desirable. Studies exploring the diagnostic utility of either podoplanin (D2-40) or E-cadherin IHC in meningiomas have conflicted, and no studies exist in which the two IHCs have been used in combination for diagnosis.
E-cadherin and D2-40 IHC was performed on 77 meningiomas (31 ordinary; eight microcystic; four rare myxoid; six metaplastic; six invasive of orbit, muscle, and/or soft tissue; two metastatic; six brain-invasive World Health Organization [WHO] grade II, nine non-brain-invasive WHO grade II; and five anaplastic WHO grade III), with semi-quantitative scoring on a three-tier scale (0, focal [1+], strong/diffuse [2+]).
All meningiomas were either E-cadherin or D2-40 IHC+, with 69 of 77 showing dual immunostaining, most at the 2+ level. No downregulation of E-cadherin IHC was found in invasive or high-grade meningiomas.
Dual E-cadherin/D2-40 IHC can supplement diagnosis of meningioma.
77例脑膜瘤（包括31例普通型；8例微囊型；4例罕见黏液型；6例化生型；6例浸润眼眶、肌肉和/或软组织；2例转移型；6例脑组织侵犯WHO2级；9例无脑组织侵犯WHO2级和5例间变性WHO3级）进行了E-cadherin和D2-40 免疫组化染色，并按照3级法（0、局灶[1+]和强/漫[2+ ]）记录半定量评分。
所有脑膜E-cadherin或D2-40 阳性，69/77显示二者双阳性，大多在2+水平。浸润型或高级别脑膜瘤 E-cadherin免疫组化没有发现下调。